Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Healthcare Technologies

This article was originally published in The Tan Sheet

Executive Summary

Uriscreen urinary tract infection home diagnostic test kit for OTC marketing gains FDA approval Oct. 7, Ashdod, Israel-based firm's Savyon Diagnostics subsidiary says. "With increased availability of treatments that offer women immediate relief from the painful symptoms of UTI, more women are seeking home screening procedures," Healthcare Technologies says. Uriscreen, which measures catalase, has a 91% accuracy level, the firm adds. Healthcare is in negotiations with a "major" pharmaceutical firm regarding North American distribution of the product, which would be marketed under the undisclosed firm's name
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088997

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel